Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05111288 · ClinicalTrials.gov registry record · NA
Influence of Pulse Electromagnetic Field Therapy on Myocardial Ischemia
A NA study of Coronary Artery Disease and Myocardial Infarction, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 2
- Study locations
NCT05111288: Recruiting NA study of Coronary Artery Disease and Myocardial Infarction, sponsored by Mayo Clinic.
NCT05111288 is a NA study of Coronary Artery Disease and Myocardial Infarction that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 120 participants, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05111288, a NA study of Coronary Artery Disease and Myocardial Infarction, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is being done to observe the effects of treatment from a device called the Bioboosti which utilizes pulsed electromagnetic waves on its ability to improve blood flow to the heart tissue in individuals with coronary artery disease (CAD).
Primary Outcome
assessment of myocardial blood flow using 13N-ammonia myocardial perfusion positron emission tomography (PET) to quantify blood flow during chemical induced stress
Conditions Studied
Interventions
- DEVICE Pulsed electromagnetic field therapy (PEMF)
- DEVICE Inactive Pulsed electromagnetic field therapy (PEMF)
Study Locations (2)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2022-05-18 |
| Est. Completion | 2026-08 |
| Phase | NA |
What NCT05111288 shows while recruiting
NCT05111288 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Pulsed electromagnetic field therapy (PEMF) is the first listed.
NCT05111288 reports a single indexed study location in Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05111288 about?
NCT05111288 is a clinical study titled "Influence of Pulse Electromagnetic Field Therapy on Myocardial Ischemia". This study is being done to observe the effects of treatment from a device called the Bioboosti which utilizes pulsed electromagnetic waves on its ability to improve blood flow to the heart tissue in individuals with coronary artery disease (CAD).
What is the current status of trial NCT05111288?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2022-05-18. Estimated completion is 2026-08.
What conditions does trial NCT05111288 study?
This clinical trial studies the following conditions: Coronary Artery Disease, Myocardial Infarction.
What interventions are being tested in trial NCT05111288?
The interventions under investigation include: Pulsed electromagnetic field therapy (PEMF) (DEVICE), Inactive Pulsed electromagnetic field therapy (PEMF) (DEVICE).
Who is sponsoring clinical trial NCT05111288?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05111288 being conducted?
This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05111288's enrollment target sits among peer trials
120 137th of 219 higher than 81 of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
RECRUITING · NA
-
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
RECRUITING · NA
-
Intravascular Lithotripsy With or Without Rotational Atherectomy for Coronary Calcified Nodule Treatment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI